Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Study of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC)

NCT05915351 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT05915351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05915351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Study of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC)
Lead sponsor
University of Kansas Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 30, 2023
Completion date
June 1, 2026
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas adenocarcinoma, pancreas cancer, pancreatic ductal adenocarcinoma